Biliary Tract Cancer
233
60
76
78
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
26 trials with published results (11%)
Research Maturity
78 completed trials (33% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.4%
22 terminated out of 233 trials
78.0%
-8.5% vs benchmark
6%
14 trials in Phase 3/4
33%
26 of 78 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 78 completed trials
Clinical Trials (233)
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
Extracellular RNA Markers of Liver Disease and Cancer
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Adebrelimab Plus S-1 for Resected Cholangiocarcinoma
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy
Study for AZD4360 in Participants With Advanced Solid Tumours
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
A Study to Evaluate the Association of Biliary Complications and Treatment Duration in Unresectable BTC Patients
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy